Clinical trial
A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
NCT00046423 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00046423 |
|---|---|
| Title | A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies |
| Official title | A Phase I Trial of ABI-007 Administered Weekly for Three Doses Every 4 Weeks in Patients With Advanced Non-hematologic Malignancies |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | ABI-007 |
| Enrollment | 20 |
| Start date | Apr 1, 2000 |
| First posted | Oct 3, 2002 |
| Last update posted | Nov 25, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: